DiDomenico Concetta, Clerico Danielle, Leahey Ann
The Children's Hospital of Philadelphia, Division of Oncology, 3401 Civic Center Boulevard, Philadelphia, Pennsylvania, 19104.
Pediatr Blood Cancer. 2015 Oct;62(10):1859-61. doi: 10.1002/pbc.25566. Epub 2015 Apr 30.
The delivery route of chemotherapy for intraocular retinoblastoma has become controversial. One objection to systemic delivery is the need for central venous access. We cross-referenced a hospital vascular access database with our tumor registry to determine the incidence of chemotherapy infiltrates. Sixty-five patients received 270 cycles of chemotherapy via peripheral intravenous access. Vincristine infiltration was 0% (95% confidence interval [CI] 0-0.16%) while that of non-vesicant chemotherapy was 0.7% (95%CI 0.1-2.6%). Giving chemotherapy via peripheral access to patients with retinoblastoma is safe. It can decrease therapy costs and prevent central line associated blood stream infections.
